Additionally, we developed a glycolysis-related gene signature (GRS) based on the expression of two biomarkers (ARNTL2 and TPX2), which serves as a prognostic signature and effectively discriminates high-risk patients in PC. Here, TPX2 is linked to pachyonychia congenita.